

Assessment of Regulatory Strategies for ANDA Submissions: Case Studies from Generic Drug Manufacturers

Mitul Tilala^{*1}, Abhip Dilip Chawda², Abhishek Pandurang Benke³

¹Independent Researcher, New Jersey, Franklin Park, USA.

²Independent Researcher, USA.

³Independent Researcher, USA.

Corresponding Author

Mitul Tilala

Independent Researcher, New Jersey, Franklin Park, USA

tilalamitul@gmail.com

Abstract

Propose: The regulatory regulations of different nations globally differ from one another. As a result, it is difficult for the corporations to create a single medication that can be concurrently filed for approval in every country. The various requirements for registration for generic medicine in the US were presented by the present research. In the United States, approved under the abbreviated new drug application are generic medications. Exclusivity rights, which prevent generic businesses from launching a product right away after patent expiration, are used to prolong a product's patent duration after it has expired. The United States (US) generic marketplace was the study's main objective.

Aim: Infringement of patents lawsuits are necessary for the approval of generic drugs prior to patent expiration since brand businesses employ strong Life Cycle Management (LCM) techniques.

Method: The study focused on three key areas: patents and exclusivities, paragraph IV of the certificates, and emerging therapeutic areas—all of which provide significant challenges for generic businesses. We conducted a case study using statistical analysis on 12 drug firms in India between 2010 and 2020 which produced 2633 US-approved generic medicines.

Results: We discovered that the majority of patent litigations involving secondary patents and new clinical indications exclusivity are filed by Indian corporations. The percentage of Indian companies in certificates increased to 18% in Paragraph IV. In contrast to pharmaceuticals for the cardiac and central nervous system, more cancer therapies were produced, according to a parallel investigation on changes in these generic medicines' therapeutic regions over the previous ten years.

Conclusion: The present research, which examined the knowledge gaps among generic and branded firms that must be filled for a successful promotion of generic pharmaceuticals, will aid in resolving the aforementioned problems.

Keywords: Generic Drugs, Indian Companies, Marketing, Generic Companies, US-Approved, Pharma Companies, Life Cycle Management (LCM) Strategies, Drug Application.

I. INTRODUCTION

The Drug Price Competitiveness and Patents Term Restoring Act of 1984 (also known as the "Hatch Waxman Act") promotes competition and promotes generic medications. The Act created the Abbreviated New Drug Application (or "ANDA"), a new procedure for generic medications to be sold [1]. "Make available more low-cost generic medicines by establishing

a generic medication approval process for pioneer drugs that were first authorised after 1962," was the stated goal of Congress' Act. Congress did, however, also attempt to find a balance via the Hatch-Waxman Act, attempting to counteract competitors' ability to enter the market with low-priced generics and the requirement that manufacturers of name-brand medications conduct investigations and develop new medications.

In order to achieve the first goal, the Hatch-Waxman Act's ANDA gave generic manufacturers access to a new approval procedure. During this process, they just need to demonstrate that their generic product is equivalent to the pioneer medication, for which the FDA had previously conducted testing and granted approval. This was done with the intention of saving generic manufacturers the substantial expenditures associated with repeating the NDA process—especially with regard to the costly data pertaining to human subjects [1, 2]. Additionally, the Act allowed generic medicine makers to petition for generic medications with different active ingredients, different dosages, or other strengths, as long as the modification did not necessitate a separate analysis of clinical data.

Hatch-Waxman also sought to continue funding innovative research and development for pharmaceuticals. In order to achieve this, the Act created the ANDA and the Section 505(b) (2) application, two new FDA pharmacological approval procedures. These approval procedures spare innovator research duplication and enable product development during inventive exclusivity periods for manufacturers of healthcare products that are equivalent, equivalent but not equivalent, and for which substantial safety and efficacy testing has previously been carried out by third parties. The Hatch Waxman Amendment also permitted generic manufactures to test develop generic medications using the patented pioneering drug during the patient's life, which might have otherwise considered patent infringement, in order to facilitate the parallel development of generics [2, 3]. Thus, generic medicine makers were able to launch a rival medication earlier on the market thanks to the release of pioneer products' testing data and private information. Nonetheless, a number of competition-related limitations were incorporated into the Hatch-Waxman Act to uphold the initial objective of preserving the incentives for scientific advancement.

First, there is a five-year exclusive a period for pioneer drugs—those with NCEs that are new to the market—during which no ANDAs can be filed. The Act mandates that manufacturers notify the holders of the patents of the associated pioneer medical treatments of any potential exclusivity infringement when generic manufacturers want to launch a bioequivalent. This allows the matter to be litigated as soon as feasible. The approval of a pharmaceutical manufacturer's ANDA is postponed for 30 months, until a court rules that the inventor's patent is not infringed, if a complaint alleging patent infringement is filed within 45 days of the notice of final certification. The generic medication manufacturer who filed the ANDA is allowed to sell and marketplace the medicinal product if, after thirty months, no federal court has determined whether or not there is patent the infringement; however, if infringing is later discovered by a court, the ANDA filer who chooses to pursue this course may then be liable for infringement harm.

The government enforces several laws and regulations in the pharmaceutical industry to safeguard public health and welfare, making it one of the most regulated sectors of the economy. Thus, the goal of pharmaceutical companies is to find and create a generic

medication product that can be modified to satisfy the different requirements of the market. Based on worldwide developments in the market, [3], it is projected that between 2010 and 2017 about \$150 billion worth of medications will become off-patent, providing an environment for generic medicine development by pharmaceutical businesses. India's pharmaceutical sector has grown remarkably, which has boosted the country's economy.

Following the implementation of India's pharmaceutical patent policy, pharmaceutical businesses operating in India and overseas were required to investigate other markets. Indian pharmaceutical companies are branching into new areas with a view to being worldwide, and their concentration is on mergers and acquisitions as a means of doing so. Companies need to focus on generic prescription items if they want to grow steadily over the next several decades. "Generic drugs have great opportunities in diseases that require management and cannot be cured." Protecting its citizens is the duty of the governing body. Establishing regulatory bodies with strict policies for drug legislation and quality control in their various regions is the duty of national governments. Officials from Japan, the EU, [4], and the US felt that more harmonisation was necessary during the International Conference of Drug Regulatory Authorities (ICDRA), which was hosted by the World Health Organisation (WHO). This felt somewhat parallel to the ongoing harmonisation and movement towards creating a unified marketplace for medications inside the EU.

1.1 Trends in Indian pharmaceutical market regulation Framework for drug regulations

The Indian federal government and the state legislatures have different levels to their drug regulating frameworks. The Ministry of Chemical and Fertilisers is primarily concerned with industrial policy, whereas the Ministry of Health and Family Welfare (MOHFW) looks at pharmacological concerns in the larger picture of public health. The primary drug regulatory body within the Ministry of Health is the Central pharmaceuticals Standards Control Organisation (CDSCO), which is in charge of setting drug standards, licencing new pharmaceuticals, conducting clinical trials, authorising industrial licences, testing drugs, and keeping an eye on adverse drug reactions. The licencing of drug formulations that are testing for drugs facilities, production sites, sale locations, and inspection for manufacturing sites and selling locations fall under the purview of the state FDAs [4, 5].

1.2 Public Demands and Legal Limitations to Federal Generic Drug Approval

Any individual or group can formally request the FDA to either start or refrain from taking specified steps by presenting a citizen petition. The FDA's regulatory framework establishes the rules for citizen petitions. It ought to arrive as no surprise that producers of novel medications have regularly challenged the FDA's decisions to approve or even anticipate approval for generic versions of their products. Often, these businesses have petitioned the FDA as citizens, arguing against the anticipated authorization for generic versions of their products. Furthermore, generic medicine businesses have the authority to file citizen petition for a variety of purposes, including ANDA appropriateness and challenges pertaining to 180-day exclusivity.

To ensure that they aren't overburdened with matters that could have been settled by first requesting relief from the administration agency, courts may mandate this "exhaustion" in order to save judiciary resource. Several times, innovator pharmaceutical companies who

have suffered because of FDA judgements about ANDA approvals have taken legal action to contest those decisions. The FDA has occasionally denied an appeal from a legitimate citizen while still agreeing to an ANDA. In analogous previous cases, [5], the FDA issued the contested ANDA approval but did not address the appeal; as a result, the innovative firm interpreted the FDA's approval as essentially rejecting their petition. Typically, the creative business has filed a lawsuit against the FDA to prevent the agency from approving the generic drug. Typically, the involved generic organisations had prior authorization to participate in the lawsuit as a party in order to protect the financial interests associated with their individual ANDA approvals.

1.3 Objectives of the study

- Evaluating the existing regulatory environment for ANDAs (abbreviated new drug applications) in order to comprehend the subtleties and intricacies of the approval procedure for generic medications.
- Determining the difficulties generic medication producers encounter when putting up and submitting ANDAs to authorities like the FDA (Food and medication Administration).
- Evaluating generic medication makers' adherence to legal requirements and industry standards and pinpointing areas in need of improvement.

II. LITERATURE REVIEW

(Patil, A., & Thakre, A. 2020) [6] Pharmaceutical product enrolment standards are taken care of by pharmaceutical medication oversight concerns. Its broad scope includes every aspect of marketing and documentation in an established framework. DRA is a vibrant, lucrative industry that combines the rational and legal aspects of the development of pharmaceuticals. DRA specialists are devoted individuals who make significant financial investments in their mission to enhance peoples' health and quality of life. As a calling, RA is more comprehensive than product enlistment; they truly and purposefully prompt organisations at the highest level. The administrative requirements that must be met in order for a drug to be approved in other countries nowadays are extremely onerous. One of the most difficult assignments, especially for companies with global operations, is to develop a consistent administrative procedure for the Marketing Authorization Applications (MAA) of a different pharmaceutical product for various countries.

(Ramakrishna, B., Nagamani, K., 2018) [7] This topic's primary goal is to discuss overcoming obstacles when filling generic products. This topic's goal is to examine and contrast the filing processes for generic drugs across various nations, as well as the difficulties they face. As an illustration: In the USA, the ANDA (Abbreviated New medication Application) is used to fill out generic medication applications. In Europe, generic medications are filled individually through the European Medicines Agency (EMA). Generic medications are sent to the Drug Controller General of India (DCGI) in India. The regulatory obstacles that Malaysia and Europe face. Access to medical personnel and services is typically concentrated in urban regions, making it challenging for those living in rural and remote regions to acquire treatment and quality medications.

(Vinaykumar, M., 2019) [8] This study aims to give sufficient details on the safety and effectiveness of medicines for humans as well as an understanding of the differences between

the laws governing bio equivalency data, drug registering, approvals process, and guidelines related with the filing of generic pharmaceuticals in the USA and China. According to the "Pharmacokinetic variables and Pharmacodynamics is" attributes, generic medications are transferable and indistinguishable from the innovative drug's counterpart at a level that is acceptable bioequivalent. For a generic medication to be licenced to successfully enter the pharmacy sector, it must adhere to the requirements set by the National Medical Product Administration in China in addition to the US Food and Drug Administration (FDA) in the USA. The medication needs to be biologically equivalent to the branded one. While in Module III in the USA there is complete details concerning Drug Substance and Drug Product, in China Module III only contains complete data about Drug Product, in the USA there is complete details about the quality overall summary in Course II.

(Martin, R., 2019) [9] Everybody's primary concern is their physical well-being, and various cultures around the world have unique methods for preventing and treating disease. Although the drug's dose form may alter, a generic medication functions in the body in ways that are comparable to more expensive brand-name medications. They obtain the same active ingredient, possess the same quality, and are required to meet the same high criteria for the production and packaging of medications. Under the Food and Drug Administration's legislation, generic medications must function and be of the same quality as name-brand medications. According to the Food and Drug Administration (FDA), "generics have the same quality as brand-name drugs." A generic drug product must satisfy stringent requirements set by the Food and Drug Administration (FDA), in order to be licenced. These requirements include identification, strength, quality, purity, and potency.

III. METHODS

3.1 Sources of data

Every piece of information needed for the research has been collected from publically accessible sources. The net sales data for individual companies was obtained from their annual reports on their website. The information about NDAs and ANDAs came from the FDA webpage. The United States District Court of Delaware's website and Insight.rpxcopr.com provided information about the patent issues and legal proceedings. The FDA's Orange Book, which covers the years 2010 through 2021, [10], is the source for the 180-day exclusiveness and therapeutic area.

3.2 Design

Based on the amount they sold for net and the total number of authorised ANDAs, the companies were chosen for the study. These businesses are publicly traded, listing on the Indian Stock Exchange, and possess ANDAs (2643), NDAs, FDA-approved medications, and net revenues exceed 2000 crore Indian rupees. 2634 authorised medications between 2010 and 2020 were taken into consideration for this analysis. Every medicine that was approved was checked for therapy area, 180-day exclusiveness, and patent concerns. Figure 1.

3.3 Examining cases involving claims of patent infringement

The number of ANDA cases that were filed in US courts between 2009 and 2020 were examined; the cases' average yearly increase was computed, and the linearity of the data was plotted. An analysis was conducted on the increase of lawsuits alleging infringement against Indian generic organisations during the last ten years [10, 11].

3.4 Examining certifications in accordance with Paragraph IV

An analysis was conducted on the percentage of Indian enterprises that claimed 180 days of exclusivity. The percentage comprised of Indian enterprises and the total number of Article IV certifications were compared, and the projected time from application to clearance was also calculated.

3.5 Analysing medication modalities and therapeutic modifications

We classified the medications based on the total number of authorised generic medications in each disease group annually during 2009 and 2020. Estimating the modifications in generic medication development throughout time and the present generic market trend allowed for the creation of a comparison graph.




Fig. 1 Areas of study for problems with generic drugs. [10].

IV. RESULTS

In 2020, 5,029 ANDAs had been submitted by Indian pharmaceutical companies. Module-1 (Administrative), Module-2 (Quality general overview), and Module-3 (Quality) comprise the electronic Common Technical Document (eCTD) format that was used to construct the ANDA. The internet-based submission portal is used to submit the finished ANDA dossier. Costs for firms vary according on the quantity of ANDAs filed; small businesses (up to 5) pay \$154,299, moderate companies (six to nineteen) \$617,197, [10], and large corporations (twenty or more) \$1,542,993. The typical schedule for reviewing ANDA is 10 months; if it is prioritised, it will take 8 months. Table 1 shows the overall amount of ANDAs filed between 2010 and 2020 as well as the percentage of Indian companies in those submissions.

Table 1 Amount of ANDAs issued annually and the share of Indian companies. [11].

Years	Approved ANDA's	Indian Entrepreneurs Share
2010	452	123 (29.6%)
2011	433	109 (63.65%)
2012	473	124 (21.96%)
2013	532	175 (22.82%)
2014	413	161 (21.09%)
2015	428	132 (31.69%)
2016	514	139 (29.60%)
2017	680	219 (54.90%)
2018	489	254 (26.92%)
2019	282	306 (30.52%)
2020	593	296 4.96%)

4.1 Cases affecting Patents

An analysis was conducted on the total amount of patent infringement lawsuits brought in US courts between 2010 and 2020 based on generic applications. Generic medicine research has been steadily increasing, not just for US corporations but also for companies worldwide. These businesses have to file a patent challenged and notify the patent holders of their intention to do so when they produce the first time generic medications for new chemicals [12]. The FDA can authorise the generic version for sales on the marketplace if the branded businesses do not file the case after 45 days of filing the ANDA. The FDA gets more generic submissions from India than from any other country, hence our analysis concentrated on patent litigation brought against Indian manufacturers of generic medicines Table 2.

Table 2 Indian pharmaceutical companies' net revenue, the quantity of approved NDAs and ANDAs. [12].

Company Name	Net sales 2020 (Indian Rupees Crores)	ANDA's as October 1, 2020	NDA's as October 1, 2020
(Aurobindo Pharm)	36,461	624	97
Cipla	16,395	296	08
Alkem	48,239	219	01
Torrent	16,238	648	09
(Alembic Pharm)	49,239	693	08
Wockhardit	54,298	679	Nil
(Strides Pharm)	97,263	643	02
Dr. Reddy's	97,269	908	Nil
(Sun Pharm)	79,369	697	07
Zydus Cadila	79,369	920	Nil
Lupin	76,384	986	Nil

4.2 Certifications for Paragraph IV

According to the 1984 Drug Price Competitive and Patents Term Restoration Act, certified feasible is provided in paragraph IV. This means that before the branded company's patents expire, generic medications manufacturers can apply for FDA approval to release their product into the marketplace. With this certification, the first firm, [13], or companies, to submit the agency-determined complete dossier, which must include one of the patent listed in the bright orange book, will have 180 days of exclusivity. The percentage of Indian enterprises was discovered to be 18% in 2020 Table 3.

Table 3 The quantity of claimed Paragraph IV certifications shared by Indian enterprises. [13].

Years	Indian Pharmaceutical Enterprises	Certifications with relation to Paragraph IV
2010	3.6	48
2011	3.8	52
2012	4.6	56
2013	4.6	62
2014	5.9	68
2015	5.2	71
2016	6.9	78
2017	6.2	79
2018	7.8	81
2019	8.9	85
2020	9.1	89

V. DISCUSSION

Branded firms invest millions of dollars in medication discovery, clinical studies, brand promotion, and marketing approvals in order to synthesise novel chemicals and create new drugs. They are unable to make the anticipated revenue due to a lack of exclusivities covered by patents. Through guaranteeing the expenses and hazards associated with novel drug discovery, corporations endeavour to garner profits from their current range of products. In this analysis, the years 2010 to 2020 were split into two segments: 2008 to 2015, which corresponded to 885 medications, and 2016 to 2020, which corresponded to 1750 pharmaceuticals. Next, we determined the percentage of medications, both in terms of formulation and therapeutics [14]. Table 5 presents the tabulated results of the comparison investigation.

Table 5 Formulation and therapeutic modifications for generic medications between 2010 and 2020. [13].

<i>Therapeutics</i>	Year	Diabetic (%)	Blood (%)	Cardio (%)	Cancer (%)	Endocrine (%)	Nervous (%)	Immune (%)	Other (%)	Total (%)
<i>Small Molecules</i>	2010	6	5	15	15	0	5	0	14	60
	2020	9	9	2	12	8	2	0	2	44
<i>Complex</i>	2010	6	9	8	18	9	4	9	8	71
	2020	5	2	9	22	1	9	5	6	59
<i>Biologicals</i>	2010	21	1	5	9	5	2	2	0	45
	2020	14	5	6	5	9	2	5	7	53
<i>Total (%)</i>	2010	5	9	5	8	8	9	4	8	56
	2020	12	19	9	20	3	9	4	0	76

The majority of US and Japanese businesses will favour extending the patent life through exclusive right. This motivates the branded businesses to have robust management teams, product portfolios, and intellectual property. By creating second-generation medications, the LCM methods will thereby balance the risk associated with expenditures in development and research efforts through current medicines [14]. A vast amount of material was gathered, examined, and evaluated in this regard in order to determine the most recent strategic decisions made by various branded businesses and how those are combined with research to maintain competitiveness once exclusivity in the market ends.

Lifecycle management refers to the sequential process that starts with product development and ends with its removal from the market [14, 15]. It will uphold specific predefined standards at every stage, minimising lost money and time. Development, approval, market launch, development, maturity, and decline are the stages that are categorised. In order to provide a specific clinical benefit, the new entities with molecules must be identified and synthesised in the appropriate dosage forms throughout the development stage. Most medications will not work during their developmental stages.

VI. CONCLUSION

In conclusion, the legislative filing procedure for generic medications in the United States is a difficult and demanding procedure with many obstacles. These difficulties include problems with the FDA's authorization procedure, legal disputes over patents, citizen petitions, exclusivity concerns, etc. In addition, there are additional obstacles for the regulatory filing of generic drug products to bring them to market due to the high cost of studying and developing them and growing competition from foreign manufacturers.

Although global harmonisation is ongoing, the pharmaceutical sector still faces significant obstacles when it comes to developing and submitting applications for generic drugs.

The number of NDAs (77) and ANDAs (2633) across the businesses chosen for the study differed significantly, indicating a glaring deficiency in research laboratories in generic companies. Evaluating several invalid secondary patents is necessary for Paragraph IV certifications, as this will enable the firms to create early generic medications for serious illnesses. We limited the size of our sample and focused solely on therapeutic regions and patent exclusivity. We anticipate that our study will help small and medium-sized generic enterprises that are creating generic versions of novel compounds in India and around the world.

VII. REFERENCES

- [1] Woodcock J. Testimony of CDER Director before the House Committee on Energy and Commerce, Subcommittee on Health – GDUFA II, BsUFA II – Dec 31, 2018; 2018.
- [2] Naziya Rafi, Sandeep DS AN V. Regulatory Requirements and Registration Procedure for Generic Drugs in USA. *Indian J Pharm Educ Res.* 2017; 51(2):S46–53.
- [3] Handoo S, Khera D, Nandi P, Sahu S, Arora V. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. *Int J Pharm Investing.* 2012; 2(3):99.
- [4] Joshi SS, Shetty YC, Karande S. Generic drugs – The Indian scenario. *J Postgrad Med [Internet].* 2019; 65(2):67.
- [5] Sai Kumari B, Sai Hanuja G, Nagabhushanam MV, Nagarjuna Reddy D, Brahmaiah Bonthagarala. Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic goods Administration, *International Journal of Advanced Scientific and Technical Research*, ISSN 2249-9954, 2016; 6 (6):144-157.
- [6] Patil, A., & Thakre, A. (2020). Overview of drug regulatory affairs and drug approval process in US, Europe, India and Canada: A review. *International Journal of Drug Regulatory Affairs*, 8(2), 36-43.
- [7] Ramakrishna, B., Nagamani, K., Padmini, C. N., Teja, S. K., & Durga, C. (2018). CHALLENGES IN REGULATORY FILING OF GENERIC PRODUCTS IN EUROPE AND MALAYSIA.
- [8] Vinaykumar, M., & Venkatesh, M. P. (2019). Comparison of regulatory requirements for filing of generic drug product in USA and China. *Journal of Pharmaceutical Sciences and Research*, 11(6), 2426-2436.
- [9] Martin, R., & Bahmani, K. (2019). Generic drugs, a need to the public: USA and India– Government plans to reduce the price of abbreviated new drug application and list of generic drugs approved in year 2018. *Journal of Generic Medicines*, 15(3), 115-132.
- [10] Gupta D B, Exciting Opportunities for the Indian Pharmaceutical Industry, *Indian Chemical Engineer*, 49 (2) (2007) 154-157.
- [11] Achilladelis B & Antonakis N, The dynamics of technological innovation: The case of the pharmaceutical industry, *Research Policy*, 30 (2001) 535-588.

- [12] Gujarati D & Porter D, Basic Econometrics, (McGraw Hill Education, India), 2011, p 63-69.
- [13] Indian Life Sciences: Vision 2030, Expanding Global Relevance and Driving Domestic Access, FICCI Life Sciences, 2014.
- [14] Srividhya SD, Sharma A. India: Pharmacy to the world; updated December 2020; [cited May 3 2021].
- [15] Sampat BN, Shadlen KC. Secondary pharmaceutical patenting: A global perspective. *Research Policy*. 2017; 46(3):693-707.
- [16] Kanungo, S. (2023). Cross-Border Data Governance and Privacy Laws. *International Journal of Open Publication and Exploration (IJOPE)*, 11(1), 44-46. Retrieved from <https://ijope.com>.
- [17] Kanungo, S. (2021). Hybrid Cloud Integration: Best Practices and Use Cases. *International Journal on Recent and Innovation Trends in Computing and Communication (IJRITCC)*, 9(5), 62-70. Retrieved from <http://www.ijritcc.org>
- [18] Kanungo, S. (2020). Decoding AI: Transparent Models for Understandable Decision-Making. *Journal of Propulsion Technology*, 41(4), 54-61. <https://ijmirm.com>
- [19] Kanungo, S., & Kumar, P. (2019). Machine Learning Fraud Detection System in the Financial Section. *Webology*, 16(2), 490-497.
- [20] Kanungo, S. (2019). Edge-to-Cloud Intelligence: Enhancing IoT Devices with Machine Learning and Cloud Computing. *International Peer-Reviewed Journal*, 2(12), 238-245. Publisher: IRE Journals.
- [21] Mohammad, Naseemuddin. "Data Integrity and Cost Optimization in Cloud Migration." *International Journal of Information Technology & Management Information System (IJITMIS)* 12, no. 1 (2021): 44-56. IAEME Publication.
- [22] Mohammad, Naseemuddin. "Enhancing Security and Privacy in Multi-Cloud Environments: A Comprehensive Study on Encryption Techniques and Access Control Mechanisms." *International Journal of Computer Engineering and Technology (IJCET)* 12, no. 2 (2021): 51-63. IAEME Publication.
- [23] Karuturi, S. R. V., Satish, Naseemuddin Mohammad. "Big Data Security and Data Encryption in Cloud Computing." *International Journal of Engineering Trends and Applications (IJETA)* 7, no. 4 (2020): 35-40. Eighth Sense Research Group.
- [24] Kaur, Jagbir. "Big Data Visualization Techniques for Decision Support Systems." *Tuijin Jishu/Journal of Propulsion Technology* 42, no. 4 (2021).
- [25] Kaur, Jagbir, et al. "AI Applications in Smart Cities: Experiences from Deploying ML Algorithms for Urban Planning and Resource Optimization." *Tuijin Jishu/Journal of Propulsion Technology* 40, no. 4 (2019): 50.
- [26] Choppadandi, Ashok, Jagbir Kaur, Pradeep Kumar Chenchala, Satyanarayan Kanungo, and Pandi Kirupa Kumari Gopalakrishna Pandian. "AI-Driven Customer Relationship Management in PK Salon Management System." *International Journal of Open Publication and Exploration (IJOPE)* 7, no. 2 (July-December 2019): 28. Available online at: <https://ijope.com>
- [27] Chenchala, Pradeep Kumar, Ashok Choppadandi, Jagbir Kaur, Varun Nakra, and Pandi Kirupa Gopalakrishna Pandian. "Predictive Maintenance and Resource Optimization in

- Inventory Identification Tool Using ML." *International Journal of Open Publication and Exploration (IJOPE)* 8, no. 2 (July-December 2020): 43. Available online at: <https://ijope.com>
- [28] Kaur, Jagbir, Ashok Choppadandi, Pradeep Kumar Chenchala, Varun Nakra, and Pandi Kirupa Gopalakrishna Pandian. "AI-Enabled Chatbots for Customer Service: Case Studies on Improving User Interaction and Satisfaction." *International Journal of Transcontinental Discoveries (IJTD)* 6, no. 1 (January-December 2019): 43. Available online at: <https://internationaljournals.org/index.php/ijtd>
- [29] Chintala, S. K., et al. (2021). Explore the impact of emerging technologies such as AI, machine learning, and blockchain on transforming retail marketing strategies. *Webology*, 18(1), 2361-2375.<http://www.webology.org>
- [30] Chintala, S. (2019). IoT and Cloud Computing: Enhancing Connectivity. *International Journal of New Media Studies (IJNMS)*, 6(1), 18-25. ISSN: 2394-4331. <https://ijnms.com/index.php/ijnms/article/view/208/172>
- [31] Chintala, S. (2018). Evaluating the Impact of AI on Mental Health Assessments and Therapies. *EDUZONE: International Peer Reviewed/Refereed Multidisciplinary Journal (EIPRMJ)*, 7(2), 120-128. ISSN: 2319-5045. Available online at: www.eduzonejournal.com
- [32] Sathishkumar Chintala. (2021). Evaluating the Impact of AI and ML on Diagnostic Accuracy in Radiology. *Eduzone: International Peer Reviewed/Refereed Multidisciplinary Journal*, 10(1), 68–75. Retrieved from <https://eduzonejournal.com/index.php/eiprmj/article/view/502>